Loading...
•
Mar 31, 2023
Geron Q1 2023 Earnings Report
Geron reported financial results for the first quarter of 2023 and provided business updates.
Key Takeaways
Geron reported a net loss of $38.1 million, or $0.07 per share, for the first quarter of 2023. As of March 31, 2023, the Company had $409.2 million in cash and marketable securities and believes it has sufficient resources to fund operating requirements through the end of the third quarter of 2025.
On track to submit a New Drug Application in the U.S. in June 2023.
Preparing for a potential U.S. commercial launch in the first half of 2024.
Planning to submit a Marketing Authorization Application in the EU in the second half of 2023.
Preparing for an EU commercial launch by the end of 2024.
Revenue by Segment
Forward Guidance
For fiscal year 2023, the Company continues to expect total expenses in the range of approximately $210 million to $220 million and non-GAAP total expenses for fiscal year 2023 to be in the range of approximately $200 million to $210 million.
Positive Outlook
- Support planned regulatory submissions in 2023
- Continued support of ongoing clinical trials, IMerge Phase 3, IMpactMF, IMproveMF and IMpress, as well as preclinical studies in lymphoid malignancies and discovery research for a next generation telomerase inhibitor
- Manufacturing commercial inventory of imetelstat
- Preparations for potential U.S. commercial launch of imetelstat in lower risk MDS
- Projected increases in headcount and interest payments on outstanding debt
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...